Genetically Reduced MTHFR Activity and Multiple Sclerosis Risk: A Protective Signal from Large-Scale GWAS
The article “Genetically reduced MTHFR activity confers protection against multiple sclerosis” presents a concise but provocative genetic epidemiology study examining whether reduced activity of methylenetetrahydrofolate reductase, encoded by MTHFR, influences susceptibility to multiple sclerosis (MS). MS is typically understood as an immune-mediated demyelinating disease in which genetic and environmental factors interact to promote pathological inflammation in the central nervous system. Against this background, the study’s central finding is striking: the MTHFR C677T variant, which reduces enzymatic activity and raises circulating homocysteine levels, was associated not with increased MS risk, but with a lower probability of developing MS.
Biological Rationale: Folate Metabolism, Homocysteine, and Immunity
MTHFR is a key enzyme in folate metabolism, catalyzing the generation of the active folate form needed for homocysteine remethylation. The common C677T missense variant reduces MTHFR activity and has been linked in previous research to elevated homocysteine and several neurological or vascular conditions. The authors emphasize that because folate metabolism is relevant to immune-cell proliferation, methylation, and inflammatory regulation, MTHFR variation is biologically plausible as a modifier of MS susceptibility. The novelty of the study lies in applying large-scale genetic datasets to resolve inconsistent findings from earlier, smaller case-control studies.
Study Design and Data Sources
The investigators used genetic association data from multiple genome-wide association studies. For homocysteine, they relied on the InCHIANTI cohort of 1,210 individuals. For MS risk, they meta-analyzed three large datasets: the IMSGC discovery GWAS, the IMSGC replication cohort, and a FinnGen–UK Biobank–Million Veteran Program meta-analysis, together comprising 43,069 MS cases. They also evaluated MS severity using data from 12,584 European-ancestry MS cases, in which severity was measured through the Age-Related Multiple Sclerosis Severity score. Table 1 of the article summarizes these cohorts, their sample sizes, ancestry composition, outcome scales, and covariate adjustment strategies.
Main Result: C677T Is Associated with Reduced MS Risk
The principal result was highly consistent across all three MS-risk datasets. Each homocysteine-raising allele of MTHFR C677T was associated with a reduced risk of MS, with a pooled odds ratio of 0.91 and a 95% confidence interval of 0.89–0.93. When scaled to a one-standard-deviation increase in genetically determined homocysteine attributable to MTHFR perturbation, the odds ratio was 0.73, suggesting a stronger effect when interpreted through the lens of genetically proxied MTHFR-related homocysteine elevation. Figure 1 on page 3 visualizes these results through forest plots, showing concordant protective associations across cohorts and limited heterogeneity.
Colocalization Supports MTHFR as the Relevant Locus
To determine whether the association reflected the C677T variant itself or nearby linked variants, the authors performed colocalization analysis across the MTHFR genomic region. This analysis yielded a posterior probability of 0.97 for a shared causal variant influencing both homocysteine levels and MS risk, with C677T identified as the candidate causal variant. The regional association plots in Figure 1, panels C and D, reinforce this interpretation by showing the genetic signal for homocysteine and MS risk around the MTHFR locus on chromosome 1. This strengthens the argument that the observed association is not merely a statistical artifact of linkage disequilibrium.
Risk Reduction Does Not Translate into Reduced Disease Severity
Importantly, the protective association was specific to MS susceptibility, not disease progression. The C677T variant showed no meaningful association with MS severity, with an estimated standard deviation change in ARMSS of −0.001 and a non-significant P value of 0.92. The authors also examined the related A1298C MTHFR variant, which has weaker effects on enzyme activity and less consistent influence on homocysteine; this variant was not associated with either MS risk or severity. These results suggest that reduced MTHFR activity may influence early disease susceptibility mechanisms rather than the neurodegenerative or resilience-related processes that shape disability accumulation after MS onset.
Interpretation, Limitations, and Future Directions
The findings raise a biologically intriguing possibility: partial reduction of MTHFR activity may create an immunological state that lowers MS risk, potentially through altered folate metabolism, homocysteine handling, or methylation-dependent regulation of B- and T-cell function. However, the authors appropriately caution against clinical overinterpretation. The effect size is modest, the analysis is largely restricted to European-ancestry datasets, folate status could not be stratified using summary-level data, and pleiotropic mechanisms independent of MTHFR cannot be fully excluded. Nevertheless, the study identifies MTHFR-mediated one-carbon metabolism as a compelling pathway for future mechanistic research, particularly in relation to immune regulation and therapeutic target discovery in MS.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Daghlas, I., Pluvinage, J. V., & Gill, D. (2025). Genetically reduced MTHFR activity confers protection against multiple sclerosis. Journal of Neuroimmunology, 578784.
